Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences (NBIX) has appointed Dr. Sanjay Keswani as Chief Medical Officer (CMO), effective June 2, 2025. Dr. Keswani, bringing over 20 years of pharmaceutical industry experience, will lead clinical development and medical affairs activities.
Dr. Keswani succeeds Dr. Eiry W. Roberts, who served as CMO for seven years and will transition to a strategic advisory role. His previous positions include CEO of ImmunoBrain, SVP and R&D Head at Hoffman La Roche, and VP at Bristol-Myers Squibb.
During her tenure, Dr. Roberts led key developments including INGREZZA indication expansion and the crinecerfont program resulting in FDA approval of CRENESSITY. She also oversaw successful Phase 2 studies for osavampator and NBI-1117568, both advancing to registrational programs this year.
Neurocrine Biosciences (NBIX) ha nominato il Dr. Sanjay Keswani come Chief Medical Officer (CMO), con effetto dal 2 giugno 2025. Il Dr. Keswani, con oltre 20 anni di esperienza nell'industria farmaceutica, guiderà lo sviluppo clinico e le attività di affari medici.
Il Dr. Keswani succede al Dr. Eiry W. Roberts, che ha ricoperto il ruolo di CMO per sette anni e passerà a un ruolo di consulenza strategica. Le sue posizioni precedenti includono CEO di ImmunoBrain, SVP e Responsabile R&D presso Hoffman La Roche, e VP presso Bristol-Myers Squibb.
Durante il suo mandato, il Dr. Roberts ha guidato sviluppi chiave, tra cui l'espansione dell'indicazione di INGREZZA e il programma crinecerfont, che ha portato all'approvazione da parte della FDA di CRENESSITY. Ha anche supervisionato studi di Fase 2 di successo per osavampator e NBI-1117568, entrambi avanzando a programmi registrativi quest'anno.
Neurocrine Biosciences (NBIX) ha nombrado al Dr. Sanjay Keswani como Director Médico (CMO), con efecto a partir del 2 de junio de 2025. El Dr. Keswani, que aporta más de 20 años de experiencia en la industria farmacéutica, liderará el desarrollo clínico y las actividades de asuntos médicos.
El Dr. Keswani sucede a la Dra. Eiry W. Roberts, quien ocupó el cargo de CMO durante siete años y pasará a un rol de asesoría estratégica. Sus posiciones anteriores incluyen CEO de ImmunoBrain, SVP y Jefe de I+D en Hoffman La Roche, y VP en Bristol-Myers Squibb.
Durante su mandato, la Dra. Roberts lideró desarrollos clave, incluyendo la expansión de la indicación de INGREZZA y el programa crinecerfont, que resultó en la aprobación de la FDA de CRENESSITY. También supervisó estudios exitosos de Fase 2 para osavampator y NBI-1117568, ambos avanzando a programas de registro este año.
Neurocrine Biosciences (NBIX)는 2025년 6월 2일부터 Dr. Sanjay Keswani를 최고 의학 책임자(CMO)로 임명했습니다. Dr. Keswani는 20년 이상의 제약 산업 경험을 바탕으로 임상 개발 및 의학 관련 활동을 이끌 것입니다.
Dr. Keswani는 7년 동안 CMO로 재직한 Dr. Eiry W. Roberts를 이어받으며, 전략 자문 역할로 전환할 예정입니다. 그의 이전 직책으로는 ImmunoBrain의 CEO, Hoffman La Roche의 SVP 및 R&D 책임자, Bristol-Myers Squibb의 VP가 있습니다.
Roberts 박사는 재임 기간 동안 INGREZZA의 적응증 확장 및 FDA의 CRENESSITY 승인으로 이어진 crinecerfont 프로그램을 포함한 주요 개발을 이끌었습니다. 또한 osavampator와 NBI-1117568에 대한 성공적인 2상 연구를 감독하여 올해 등록 프로그램으로 진행되었습니다.
Neurocrine Biosciences (NBIX) a nommé Dr. Sanjay Keswani au poste de Directeur Médical (CMO), à compter du 2 juin 2025. Dr. Keswani, fort de plus de 20 ans d'expérience dans l'industrie pharmaceutique, dirigera le développement clinique et les activités médicales.
Dr. Keswani succède à Dr. Eiry W. Roberts, qui a occupé le poste de CMO pendant sept ans et passera à un rôle de conseil stratégique. Ses postes précédents incluent CEO d'ImmunoBrain, SVP et Responsable R&D chez Hoffman La Roche, et VP chez Bristol-Myers Squibb.
Au cours de son mandat, Dr. Roberts a dirigé des développements clés, y compris l'expansion de l'indication de INGREZZA et le programme crinecerfont, qui a abouti à l'approbation de la FDA de CRENESSITY. Elle a également supervisé des études de phase 2 réussies pour osavampator et NBI-1117568, qui avancent tous deux vers des programmes d'enregistrement cette année.
Neurocrine Biosciences (NBIX) hat Dr. Sanjay Keswani zum Chief Medical Officer (CMO) ernannt, mit Wirkung zum 2. Juni 2025. Dr. Keswani bringt über 20 Jahre Erfahrung in der Pharmaindustrie mit und wird die klinische Entwicklung sowie die medizinischen Angelegenheiten leiten.
Dr. Keswani folgt auf Dr. Eiry W. Roberts, die sieben Jahre lang CMO war und in eine strategische Beratungsrolle wechseln wird. Zu seinen vorherigen Positionen gehören CEO von ImmunoBrain, SVP und Leiter der F&E bei Hoffman La Roche sowie VP bei Bristol-Myers Squibb.
Während ihrer Amtszeit leitete Dr. Roberts wichtige Entwicklungen, darunter die Erweiterung der Indikation von INGREZZA und das crinecerfont-Programm, das zur FDA-Zulassung von CRENESSITY führte. Sie beaufsichtigte auch erfolgreiche Phase-2-Studien für osavampator und NBI-1117568, die beide in diesem Jahr in Registrierungsprogramme übergehen.
- Two drug candidates (osavampator and NBI-1117568) advancing to registrational programs
- Recent FDA approval obtained for CRENESSITY
- Incoming CMO brings expertise in diverse treatment modalities including small molecule, peptide, antibody and gene therapy
- Successful indication expansion achieved for INGREZZA
- None.
- Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas
"Sanjay brings a wealth of strategic and development expertise to our team, enhancing our capabilities as we enter an exciting and pivotal time for the company," said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. "His contributions will extend our reach beyond small molecule medicines, enabling us to explore new modalities across our therapeutic areas of focus."
"I am thrilled to be joining Neurocrine at this stage of the company's evolution. I am drawn by Neurocrine's enduring R&D commitment to developing much-needed treatments for patients using a rigorous scientific approach involving diverse modalities, including small molecule, peptide, antibody and gene therapy," Dr. Keswani said.
Dr. Keswani has more than two decades of executive leadership experience across both large pharmaceutical companies and small biotechnology firms – and was instrumental in the development of several first-in-class and best-in-class approved medicines. Before joining Neurocrine, he was the President and Chief Executive Officer of ImmunoBrain, a clinical-stage biotechnology firm focused on developing therapeutics that leverage endogenous neuroimmune communication to promote brain repair in patients with neurodegenerative diseases. Dr. Keswani will continue to serve on ImmunoBrain's board of directors. Before that, he was Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche. Earlier, he was Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas, including immunology, neuroscience, rare diseases, fibrosis and virology.
Dr. Keswani is an elected Fellow of the Royal College of Physicians,
During her tenure, Dr. Roberts led indication expansion efforts for INGREZZA® (valbenazine) capsules and the crinecerfont development program that led to
"Since joining Neurocrine in 2018, Eiry has made enormous positive contributions that helped us become the company we are today," Dr. Gano said. "She built an outstanding clinical development team and broadened our internal capabilities, which are now a competitive advantage. We are grateful to continue benefiting from her experience and expertise as she transitions into a strategic advisory role for the company."
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, and Facebook. (*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY is a trademark of Neurocrine Biosciences, Inc.
Forward Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding our ability to execute on the Company's clinical development plans, including investigating new modalities in neurology and immunology, and the contributions Dr. Keswani may make in his role with the Company. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: the risk that the Company may not complete the leadership transition within currently anticipated timelines or at all; challenges that the Company may encounter in implementing the leadership transition; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this presentation after the date hereof other than as required by law.
© 2025 Neurocrine Biosciences, Inc. All Rights Reserved. 04/2025
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-appoints-dr-sanjay-keswani-as-chief-medical-officer-302420443.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will Dr. Sanjay Keswani start as CMO at Neurocrine Biosciences (NBIX)?
What are Dr. Keswani's previous leadership positions before joining NBIX?
What major achievements did Dr. Eiry Roberts accomplish during her tenure as NBIX CMO?
What will happen to former NBIX CMO Dr. Eiry Roberts?
